We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Cells in Blood Manipulated and Sorted Via Ferrofluids

By LabMedica International staff writers
Posted on 16 Dec 2009
Technology that uses magnetizable liquids (ferrofluids) to rapidly manipulate and sort different cells in blood, could dramatically improve the speed and sensitivity of tests used to detect cancer biomarkers, blood disorders, viruses, and other diseases. The new method does not require attaching biomarkers, or labels to the cells thus eliminating labor-intensive preparation or postprocessing.

Ferrofluids comprise magnetic nanoparticles suspended throughout a liquid carrier. A biocompatible ferrofluid--one with the right pH level and salinity so that human cells can survive in it for several hours—was developed together with a device that has integrated electrodes that generate a magnetic field pattern.

The magnetic field attracts the nanoparticles in the ferrofluid, effectively pushing and shuffling the much larger, nonmagnetic cells along specific channels. Depending on the frequency of the magnetic field applied different types of cells are manipulated and sorted according to their size, elasticity, and shape.

Being able to effectively sort and move cells with this technique could allow for much greater efficiency in disease detection. Many of today's tests require hours or even days to complete, because the concentration of diseased cells in a blood sample may be so low that it takes a long time for them to randomly bump into the sensors. For example, in early-stage cancer there could be one tumor cell for every billion healthy cells, making the cells extremely difficult to detect.

The new technology was developed by a team of scientists led by Hur Koser, associate professor at the Yale School of Engineering & Applied Science (New Haven, CT, USA) together with colleagues at the Deutsches Elektronen-Synchrotron (DESY; Hamburg, Germany) and University of Georgia (Athens, GA, USA). The findings were published in the December 7, 2009 online edition of the Proceedings of the National [U.S.] Academy of Sciences (PNAS).

Related Links:
Yale School of Engineering & Applied Science
Deutsches Elektronen-Synchrotron
University of Georgia


Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Online QC Software
Acusera 24•7
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]

Latest Hematology News

Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
16 Dec 2009  |   Hematology

Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
16 Dec 2009  |   Hematology

Higher Ferritin Threshold May Improve Iron Deficiency Detection in Children
16 Dec 2009  |   Hematology



ADLM